February 20, 2018 – Investment supports emerging entrepreneurial scientists and critical proof-of-principle studies.
Read More from FACIT Announces Latest Round of Investments Under Prospects Fund
Category: News
FACIT Start-up Turnstone Biologics Closes USD $41M Financing
November 2, 2016 – FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.
Read More from FACIT Start-up Turnstone Biologics Closes USD $41M Financing
Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers
June 23, 2016 – The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.
Read More from Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers
FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management
October 28, 2015 – Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential.
Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers
January 7, 2015 – TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets.
Fluorinov, FACIT and OICR announce novel candidate drugs
April 24, 2014 – The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects.
Read More from Fluorinov, FACIT and OICR announce novel candidate drugs